Rasio cepet: AxoGen, Inc. (AXGN)

This chart of AxoGen, Inc. (AXGN) stock quotes demonstrates the dynamics of a company attracting leading physicians and engineers with the idea of nerve fiber regeneration. The current ratio is 10.85. The business relies on purchasing biomaterials from third-party organizations, delegating their processing to external partners. Growing demand for Avance matrices in surgery ensures a profit inflow while new medical indications are being prepared.

The investor assesses the margin of safety for AxoGen, Inc. (AXGN) through its ability to cover short-term debts exclusively with cash and accounts receivable, ignoring less liquid inventories. Amid the expansion of surgical grafts into reconstructive medicine, a liquidity check via the acid test confirms the business's financial stability, identifying the asset as reliable in terms of operational viability.